News - Pharmaphorum

Latest News

in News News

Vertex and NHS close in on cystic fibrosis drug pricing deal
April 23, 2018 Share
X
Vertex and NHS close in on cystic fibrosis drug pricing deal
https://pharmaphorum.com/news/vertex-and-nhs-closing-in-on-cf-drug-pricing-deal/
in News News

NHS gene sequencing project may fail to meet objectives – report
April 23, 2018 Share
X
NHS gene sequencing project may fail to meet objectives – report
https://pharmaphorum.com/news/nhs-genomics-under-pressure-due-to-infrastructure-delays/
in News

Takeda woos Shire shareholders with increased bid
April 23, 2018 Share
X
Takeda woos Shire shareholders with increased bid
https://pharmaphorum.com/news/takeda-woos-shire-shareholders-with-increased-bid/
in News News

Novartis and Pear to develop substance use digital therapeutics
April 23, 2018 Share
X
Novartis and Pear to develop substance use digital therapeutics
https://pharmaphorum.com/news/novartis-digital-therapeutics-sandoz-pear/

Takeda woos Shire shareholders with increased bid

Fourth and probably final bid has increased cash component

Takeda woos Shire shareholders with increased bid

https://pharmaphorum.com/news/takeda-woos-shire-shareholders-with-increased-bid/

Novartis and Pear to develop substance use digital therapeutics

Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid

Novartis and Pear to develop substance use digital therapeutics

https://pharmaphorum.com/news/novartis-digital-therapeutics-sandoz-pear/

UK biotech ‘unicorn’ BenevolentAI raises cash for further expansion

R&D firm recently invested in Cambridge R&D base

UK biotech ‘unicorn’ BenevolentAI raises cash for further expansion

https://pharmaphorum.com/news/uk-biotech-unicorn-benevolentai-raises-cash-for-further-expansion/

See all

This week’s news

UK pharma calls for cooperation as EMA continues Brexit split

Britain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the

UK pharma calls for cooperation as EMA continues Brexit split

https://pharmaphorum.com/news/uk-pharma-calls-for-cooperation-as-ema-continues-brexit-split/

FDA advisers back GW’s Epidiolex for rare epilepsy

UK firm’s potential blockbuster on course for approval

FDA advisers back GW’s Epidiolex for rare epilepsy

https://pharmaphorum.com/news/fda-advisers-back-gws-epidiolex-for-rare-epilepsy/

Allergan says not interested in buying Shire

Allergan has said it is not interested in buying Shire after all, after announcing yesterday that it was

Allergan says not interested in buying Shire

https://pharmaphorum.com/news/allergan-says-not-interested-in-buying-shire/

P&G buys Merck KGaA’s consumer health unit for $4.2bn

Merck KGaA is to sell its consumer health business to Procter and Gamble for $4.2 billion, continuing the

P&G buys Merck KGaA’s consumer health unit for $4.2bn

https://pharmaphorum.com/news/pg-buys-merck-kgaas-consumer-health-unit-4-2bn/

Amazon shelves plans to sell drugs to hospitals – report

Online retailer was unable to convince big hospitals to sign up

Amazon shelves plans to sell drugs to hospitals – report

https://pharmaphorum.com/digital-health/amazon-shelves-plans-to-sell-drugs-to-hospitals-report/

Spectacular results for bluebird’s gene therapy in thalassemia

Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird

Spectacular results for bluebird’s gene therapy in thalassemia

https://pharmaphorum.com/news/spectacular-results-for-bluebirds-gene-therapy-in-thalassemia/

AZ’s Tagrisso approved for untreated lung cancer in US

Tagrisso outperformed first-generation TKI drugs in FLAURA trial

AZ’s Tagrisso approved for untreated lung cancer in US

https://pharmaphorum.com/news/azs-tagrisso-approved-untreated-lung-cancer-us/

VC digital health funding reached record $2.5bn in Q1

Roche’s $1.9bn Flatiron Health buy was standout deal

VC digital health funding reached record $2.5bn in Q1

https://pharmaphorum.com/news/vc-digital-health-funding-reached-record-2-5bn-q1-report/

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat

Novartis/Amgen migraine jab works in tough-to-treat patients

https://pharmaphorum.com/news/novartis-amgen-migraine-jab-works-tough-treat-patients/

Gottlieb sets out vision for more transparent FDA, better rare disease guidance

The FDA got a vote of confidence from the Trump administration when it recommended increasing its budget in

Gottlieb sets out vision for more transparent FDA, better rare disease guidance

https://pharmaphorum.com/news/gottlieb-sets-vision-transparent-fda-better-rare-disease-guidance/

GW prepares US for cannabis-based epilepsy drug

GW pushing for legal clearance in some states

GW prepares US for cannabis-based epilepsy drug

https://pharmaphorum.com/news/fda-reviewers-back-gw-pharmas-epilepsy-drug/

Novartis invests $100m in new malaria drugs

Concerns are mounting over resistance to artemisinin

Novartis invests $100m in new malaria drugs

https://pharmaphorum.com/news/novartis-invests-100m-new-malaria-drugs/

Roche haemophilia drug gets fast FDA review in expanded use

The FDA has granted ‘Breakthrough Therapy’ status for Roche’s Hemlibra (emicizumab) for people with haemophilia A without factor

Roche haemophilia drug gets fast FDA review in expanded use

https://pharmaphorum.com/news/roches-haemophilia-drug-breakthrough-expanded-use-fda/

Google interested in Nokia digital health unit

Google subsidiary Nest is reportedly interested in bidding for Nokia’s digital health division, which the Finnish company has

Google interested in Nokia digital health unit

https://pharmaphorum.com/news/google-interested-in-nokia-digital-health-unit/

‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.

‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade

https://pharmaphorum.com/news/keytruda-lung-cancer/

Partner content

Press releases

Key reasons to attend SMi’s Pre-Filled Syringes West Coast Conference

https://pharmaphorum.com/partner-content/key-reasons-to-attend-smis-pre-filled-syringes-west-coast-conference/

“The Changing Face of Palliative Care”: EuHIC 2018 Berlin

https://pharmaphorum.com/partner-content/the-changing-face-of-palliative-care-euhic-2018-berlin/

Past Attendee List released in advance of 8th annual BioBanking conference

https://pharmaphorum.com/partner-content/past-attendee-list-released-in-advance-of-8th-annual-biobanking-conference/

Exclusive Interview Released from NIBSC-MHRA

https://pharmaphorum.com/partner-content/exclusive-interview-released-from-nibsc-mhra/

See all

Appointments

Dominic Tyer joins pharmaphorum’s specialist healthcare content consultancy

https://pharmaphorum.com/partner-content/appointments/dominic-tyer-joins-pharmaphorums-specialist-healthcare-content-consultancy/

Makara Health Expands Senior Team with Hire of Director Louise Finke

https://pharmaphorum.com/partner-content/makara-health-expands-senior-team-with-hire-of-director-louise-finke/

See all

Search

Advanced Search

Trending

Latest News

This week’s news

Press releases

Appointments